B
Bull
Bull · 25%PLRZ
$0.90
情景价格
$12.510
-1.611 (-12.88%)收盘时
Loading chart…
- High
- 14.963
- Open
- 14.080
- VWAP
- 13.33
- Vol
- 133.77K
- Mkt Cap
- —
- Low
- 12.510
- Amount
- 1.78M
- EV/EBITDA, TTM
- 0.00
Polyrizon Ltd is an Israel-based biotechnology company. The Company is primarily engaged and specializing in the development of medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Its naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a biological mask with a thin shield containment barrier in the nasal cavity. The Company is focused not only on the development of intranasal products, but also on commercialization. The Company cooperates with medical specialists and researchers..
AI analysis of Polyrizon Ltd (PLRZ)
buyPolyrizon Ltd. is a good buy right now due to its recent patent application announcement which boosted shares by 15.55%, and a strong 1-year change of +104.75%. The current RSI of 77.967 indicates strong momentum, although it is approaching overbought territory. The main risk is the negative EPS forecast of -804.87 for Q4 2024, which could impact investor sentiment if not addressed.
估值指标
The current forward P/E ratio for Polyrizon Ltd (PLRZ) is 0.00, compared to its 5-year average forward P/E of 0.00.
Alphio AI Price Scenarios for PLRZ
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
事件时间线
资讯
8.509-03NASDAQ.COMPolyrizon Secures $4 Million Financing Through Direct Offering and Private Placement
8.509-02NewsfilterPolyrizon Completes Clinical Site Contracts for NASARIX™ Study
- 2.008-20Newsfilter
Polyrizon Completes Contracts with All Five U.S. Clinical Sites for NASARIX™ Study
9.507-31GlobenewswirePolyrizon Files Annual Report for 2025
- 8.507-02Newsfilter
Polyrizon Completes Successful Biocompatibility Evaluation for NASARIX Allergy Blocker
PLRZ FAQ — answered by Alphio AI
Polyrizon Ltd is an Israel-based biotechnology company. The Company is primarily engaged and specializing in the development of medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Its naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a biological mask with a thin shield containment barrier in the nasal cavity. The Company is focused not only on the development of intranasal products, but also on commercialization. The Company cooperates with medical specialists and researchers.. It operates in the Healthcare sector.
Polyrizon Ltd. is a good buy right now due to its recent patent application announcement which boosted shares by 15.55%, and a strong 1-year change of +104.75%. The current RSI of 77.967 indicates strong momentum, although it is approaching overbought territory. The main risk is the negative EPS forecast of -804.87 for Q4 2024, which could impact investor sentiment if not addressed.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。